Arthrosis

Autologous fibrin acts as an excellent system of gradual local release of growth factors, largely responsible for the clinical efficacy of the treatment.

Endoret® (PRGF®) technology is specifically indicated for arthrosis. Its application can slow the progress of the disease, reduce pain and inflammation and improve patient mobility and quality of life, with no side effects.

Endoret® (PRGF®) is the only plasma rich in growth factors that have been proven to be effective in two clinical trials at level one evidence.

Indications

Endoret® (PRGF®) is indicated as a treatment for arthrosis of the hips, knees, and hands. The degrees of arthrosis to be treated are: grade I, II or III (according to the Ahlback scale)

Benefits

• Delays progression of the arthrosis

• Reduces inflammation and pain effectively

• Lessens joint rigidity

• Improves the patient’s function and mobility

• Improves the patient’s quality of life